Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ProA study in mHSPC treated with apalutamide
ChiCTR2600135804Phase 4Completed
- Sponsor
- Sun Yat-sen University Cancer Center
- Start
- Nov 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of apalutamide in prostate cancer (PCa), sponsored by Sun Yat-sen University Cancer Center. Primary endpoint: Change in FACT-P total score from baseline at 6 months. Started Nov 2024; status: completed.
02
Drugs
apalutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on ChiCTR2600135804.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600135804.